Literature DB >> 27128728

Myelin Oligodendrocyte Glycoprotein-Associated Pediatric Central Nervous System Demyelination: Clinical Course, Neuroimaging Findings, and Response to Therapy.

Salini Thulasirajah1, Daniela Pohl1, Jorge Davila-Acosta1, Sunita Venkateswaran1.   

Abstract

Under the umbrella of pediatric-acquired demyelinating syndromes, there is a multitude of disorders, including optic neuritis, transverse myelitis, acute disseminated encephalomyelitis (ADEM), multiple sclerosis (MS), and neuromyelitis optica spectrum disorders (NMOSD). Due to overlapping clinical and magnetic resonance imaging (MRI) features, it can be challenging to provide an accurate diagnosis. In view of therapeutic and prognostic implications, an early and reliable diagnosis is however of utmost importance. Recent studies of myelin oligodendrocyte glycoprotein (MOG) identify MOG, as a promising target for antibody-mediated demyelination and a biomarker for a relatively benign and non-MS disease course. We describe the clinical and MRI presentation of five children presenting with an acute, severe central nervous system inflammatory disease involving the brain and spinal cord, all of whom were positive for MOG-IgG antibody. Encephalopathy was uncommon at presentation and all had quick resolution of symptoms with intravenous steroid and intravenous immunoglobulin (IVIG) treatment. All patients recovered well, and have been treated with IVIG to potentially prevent relapses. Georg Thieme Verlag KG Stuttgart · New York.

Entities:  

Mesh:

Substances:

Year:  2016        PMID: 27128728     DOI: 10.1055/s-0036-1583184

Source DB:  PubMed          Journal:  Neuropediatrics        ISSN: 0174-304X            Impact factor:   1.947


  6 in total

Review 1.  Pediatric Optic Neuritis: What Is New.

Authors:  Mark Borchert; Grant T Liu; Stacy Pineles; Amy T Waldman
Journal:  J Neuroophthalmol       Date:  2017-09       Impact factor: 3.042

Review 2.  Atypical Pediatric Demyelinating Diseases of the Central Nervous System.

Authors:  Regina M Troxell; Alison Christy
Journal:  Curr Neurol Neurosci Rep       Date:  2019-11-26       Impact factor: 5.081

3.  MRI of the first event in pediatric acquired demyelinating syndromes with antibodies to myelin oligodendrocyte glycoprotein.

Authors:  Matthias Baumann; Astrid Grams; Tanja Djurdjevic; Eva-Maria Wendel; Christian Lechner; Bettina Behring; Astrid Blaschek; Katharina Diepold; Astrid Eisenkölbl; Joel Fluss; Michael Karenfort; Johannes Koch; Bahadir Konuşkan; Steffen Leiz; Andreas Merkenschlager; Daniela Pohl; Mareike Schimmel; Charlotte Thiels; Barbara Kornek; Kathrin Schanda; Markus Reindl; Kevin Rostásy
Journal:  J Neurol       Date:  2018-02-08       Impact factor: 4.849

4.  Comprehensive analysis of patients with neuromyelitis optica spectrum disorder (NMOSD) combined with chronic hepatitis B (CHB) infection and seropositive for anti-aquaporin-4 antibody.

Authors:  Jia Liu; Li Xu; Zhuo-Lin Chen; Min Li; Huan Yi; Fu-Hua Peng
Journal:  Bosn J Basic Med Sci       Date:  2018-02-20       Impact factor: 3.363

5.  Clinical spectrum and IgG subclass analysis of anti-myelin oligodendrocyte glycoprotein antibody-associated syndromes: a multicenter study.

Authors:  Sara Mariotto; Sergio Ferrari; Salvatore Monaco; Maria Donata Benedetti; Kathrin Schanda; Daniela Alberti; Alessia Farinazzo; Ruggero Capra; Chiara Mancinelli; Nicola De Rossi; Roberto Bombardi; Luigi Zuliani; Marco Zoccarato; Raffaella Tanel; Adriana Bonora; Marco Turatti; Massimiliano Calabrese; Alberto Polo; Antonino Pavone; Luisa Grazian; GianPietro Sechi; Elia Sechi; Daniele Urso; Rachele Delogu; Francesco Janes; Luciano Deotto; Morena Cadaldini; Maria Rachele Bianchi; Gaetano Cantalupo; Markus Reindl; Alberto Gajofatto
Journal:  J Neurol       Date:  2017-10-23       Impact factor: 4.849

Review 6.  Myelin Oligodendrocyte Glycoprotein: Deciphering a Target in Inflammatory Demyelinating Diseases.

Authors:  Patrick Peschl; Monika Bradl; Romana Höftberger; Thomas Berger; Markus Reindl
Journal:  Front Immunol       Date:  2017-05-08       Impact factor: 7.561

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.